Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: Final results of an international randomized phase II study (NAVotrial 01)

Clinical Lung Cancer

Volumn 15, Issue 4, 2014, Pages 258-265

  Bennouna, Jaafar ^a   Havel, Libor ^b   Krzakowski, Maciej ^c   Kollmeier, Jens ^d   Gervais, Radj ^e   Dansin, Eric ^f   Serke, Monika ^g   Favaretto, Adolfo ^h   Szczesna, Aleksandra ⁱ   Cobo, Manuel ^j   Ciuffreda, Libero ^k   Jassem, Jacek ^l   Nicolini, Mario ^m   Ramlau, Rodryg ⁿ   Amoroso, Domenico ^o   Melotti, Barbara ^p   Almodovar, Teresa ^q   Riggi, Marcello ^r   Caux, Noël Raphaël ^r   Vaissière, Nathalie ^r   Tan, Eng Huat ^s   more..

^a UMR INSERM U892 CNRS 6299   (France)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g LUNGENKLINIK HEMER   (Germany)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ Department of Oncology Mazowieckie Centrum ChorobPluciGruzlicy   (Poland)

^j Hospital MI Carlos Haya   (Spain)

^k MOLINETTE HOSPITAL   (Italy)

^l MEDICAL UNIVERSITY OF GDANSK   (Poland)

^m Ospedale Cervesi   (Italy)

ⁿ GREATER POLAND CANCER CENTRE   (Poland)

^o Ospedale Versilia   (Italy)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^r INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^s DIVISION OF MEDICAL ONCOLOGY   (Singapore)

more..

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Nonsquamous histologic subtype; Pemetrexed; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE; PEMETREXED; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONSQUAMOUS LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; INTERNATIONAL COOPERATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; SURVIVAL;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; FEMALE; GLUTAMATES; GUANINE; HUMANS; INTERNATIONAL COOPERATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 84903174830     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.04.007     Document Type: Article

References (40)

1. D.S. Ettinger, W. Akerley, and H. Borghaei et al. Non-small cell lung cancer: clinical practice guidelines in oncology J Natl Compr Canc Netw 10 2012 1236 1271
2. S. Peters, A.A. Adjei, and C. Gridelli et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 suppl 7 2012 vii56 vii64
3. P.J. Souquet, E.H. Tan, and J. Rodrigues Pereira et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients Ann Oncol 13 2002 1853 1861
4. G.V. Scagliotti, F. De Marinis, M. Rinaldi Italian Lung Cancer Project Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
5. K. Kelly, J. Crowley, and P.A. Bunn Jr. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
6. M. Reck, J. von Pawel, and P. Zatloukal et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
7. J.H. Schiller, D. Harrington, and C.P. Belani et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
8. G.V. Scagliotti, P. Parikh, and J. von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
9. International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
10. J.Y. Douillard, R. Rosell, and M. De Lena et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 2006 719 727
11. A. Charles, C.A. Butts, and K. Dinj et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10 J Clin Oncol 28 1 2010 29 34
12. J. Jassem, P. Kosmidis, and R. Ramlau et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small cell lung cancer (NSCLC) Ann Oncol 14 2003 1634 1639
13. L.H. Jensen, K. Osterlind, and C. Rytter Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC Lung Cancer 62 2008 85 91
14. M. De Lena, R. Ramlau, and O. Hansen et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC Lung Cancer 48 2005 129 135
15. E.H. Tan, J. Rolski, and T. Grodzki et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and intravenous vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer Ann Oncol 20 2009 1249 1256
16. O. Flotten, B.F. Gronberg, and R. Bremnes et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group Br J Cancer 107 2012 442 447
17. R. Rami-Porta, J.J. Crowley, and P. Goldstraw The revised TNM staging system for lung cancer Ann Thorac Cardiovasc Surg 15 2009 4 9
18. D.A. Karnofsky, and J.H. Burchenal Evaluation of chemotherapeutic agents C.M. MacLeod, The clinical evaluation of chemotherapeutic agents in cancer 1949 Columbia University Press New York 196
19. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
20. S.G. Arbuck, S.P. Ivy, and A. Setser et al. The revised Common Toxicity Criteria: version 2.0 1999 Cancer Therapy Evaluation Program Bethesda, MD Available at: http://ctep.cancer.gov/reporting/ctc.html Accessed: May 25, 2014
21. ICH Expert Working Group. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1). Available at: http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline. pdf. Accessed: May 21, 2014.
22. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the control clinical trial Biometrics 31 1975 103 115
23. P. Pizzo Management of fever in patients with cancer and treatment-induced neutropenia N Engl J Med 328 1993 1323 1332
24. T.R. Fleming One-sample multiple testing procedure for phase II clinical trials Biometrics 38 1982 143 151
25. R. Pirker, J.R. Pereira, and A. Szczesna et al. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study Lung Cancer 77 2012 376 382
26. J. Bennouna, H. Senellart, and S. Hiret et al. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial Lung Cancer 74 2011 30 34
27. G. Scagliotti, T. Brodowicz, and F.A. Shepherd et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
28. J.D. Patel, M.A. Socinski, and E.B. Garon et al. PointBreak: a randomized phase iii study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer J Clin Oncol 31 2013 4349 4357
29. B.H. Grønberg, R.M. Bremnes, and Fløtten ∅ et al. Phase III study by the norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 27 2009 3217 3224
30. J. Rodrigues-Pereira, J.H. Kim, and M. Magallanes et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 1907 1914
31. P. Ceppi, M. Volante, and S. Saviozzi et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596
32. V. Monica, G.V. Scagliotti, and P. Ceppi et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung Clin Cancer Res 15 2009 7547 7552
33. G. Selvaggi, L. Righi, and P. Ceppi et al. Relationship of thymidylate synthase levels to outcome of malignant pleural mesothelioma patients treated with pemetrexed-based chemotherapy J Clin Oncol 27 suppl 2009 15s abstract 7508
34. M. Nicolson, K.M. Kerr, and N.H. Riyaz et al. Correlation between thymidilate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (PEM) for advanced NSCLC: A prospective Study J Clin Oncol 30 suppl 2012 abstract 7583
35. R. James, S. Barni, and L.F. von Weikersthal et al. Improving chemotherapy capacity by switching from IV to oral vinorelbine Eur J Oncol Pharm 4 2010 14 18
36. M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann Oncol 19 2008 212 222
37. L. Fallowfield, L. Atkins, and S. Catt et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer Ann Oncol 17 2006 205 210
38. A. Favaretto, L. Ciuffreda, and M. Nicolini et al. Oral vinorelbine (NVBo) plus cisplatin (CDDP) versus pemetrexed (PEM) plus CDDP followed by maintenance with single agent NVBo or PEM as first-line treatment of patients (pts) with advanced nonsquamous non small cell lung cancer (NS-NSCLC): a cost minimization analysis from the Italian National Health System (NHS) perspective Eur J Cancer 49 2013 329
39. R. Dickson, A. Bagust, and A. Boland et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal Pharmacoeconomics 29 2011 1051 1062
40. J. Greenhalgh, C. McLeod, and A. Bagust et al. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer Health Technol Assess 14 suppl 2 2010 33 39